Hilary Tindle, MD, MPH, associate professor of medicine, Vanderbilt University, discusses the nicotine metabolite ratio (NMR) is and how it's used to help identify vulnerable individuals for lung cancer and heart disease.
The nicotine metabolite ratio (NMR) is a genetically informed biomarker that shows how nicotine is broken down by the body and varies across individuals, says Hilary Tindle, MD, MPH, associate profesor of medicine, Vanderbilt University.
Transcript
What is the NMR and how does faster metabolism contribute to a “high-risk” endophenotype?
The nicotine metabolite ratio is a genetically informed biomarker. And all it is, is the ratio or fraction of 2 breakdown products of nicotine. Nicotine in a cigarette is broken down by the liver, and nicotine has a very short half-life of only about 2 hours. But that varies a lot according to a person's genetic makeup. People who tend to break down nicotine faster are heavier smokers, they tend to smoke more, they have more difficulty quitting; therefore, they smoke for more years of their life. And therefore, they are at higher risk of smoking-related diseases, such as lung cancer and heart disease.
The nicotine metabolite ratio can be measured in blood, saliva, or even urine by a doctor. It's used in the hospital, for example, before a surgery to verify if an individual is continuing to smoke or has successfully quit smoking—but this ratio is very important for quitting. So again, people who have a higher nicotine metabolite ratio, 0.31 or higher is a commonly used cut off, those folks probably have a harder time quitting and they may even need different medication.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More